Details
Simbrinza Indications
Reduction of increased intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension, in whom monotherapy did not lead to a sufficient reduction in intraocular pressure.
Contradictions
Hypersensitivity to the active substances or to any of the components of the drug.
Use of monoamine oxidase inhibitors (MAOIs) (see section "Interaction with other medicinal products and other forms of interaction.").
Use of antidepressants that affect noradrenergic transmission (eg, tricyclic antidepressants and mianserin) (see section “Interaction with other medicinal products and other forms of interaction”).
Severe renal impairment (see section "Peculiarities").
Hyperchloremic acidosis.
Newborns and infants under 2 years of age (see section "Special warnings and precautions for use").
Dosage & Administration
The patient should be advised to shake the vial well before use.
Systemic absorption is reduced if pressed in the area of the nasolacrimal opening or close the eyelids for 2 minutes. This reduces systemic side effects and increases local activity (see section "Special warnings and precautions for use").
To prevent contamination of the dropper tip and the contents of the vial, be careful not to touch the eyelids, adjacent areas or other surfaces with the tip of the dropper vial.
Patients should be advised to close the vial tightly after applying the drops.
Simbrinza® can be used concomitantly with other topical ophthalmic drugs to reduce intraocular pressure. If more than one ophthalmic agent is applied topically, the interval between their use should be at least 5 minutes.
If a dose is missed, treatment should be continued with the next dose according to the treatment regimen. The dose should not exceed one drop in the affected eye (s) twice 2 times a day.
You have no items to compare.